Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportEarly Phase (Phase 0 or I) human studies

Impact of Pre-Administration of Anti-IGF-1R Antibody FPI 1175 on the Dosimetry, Tumor Uptake, and Pharmacokinetics of the IGF-1R Targeted Theranostic Imaging Agent [111In] FPI 1547 in Patients with Solid Tumors

Andrew Scott, Fred Saad, Daniel Juneau, Michael Brown, Ian Kirkwood, Michelle Nottage, John Rhoden, Julia Kazakin, Joanne Schindler, Nicholas Baca, Richard Sparks, James OLeary and Eric Burak
Journal of Nuclear Medicine August 2022, 63 (supplement 2) 2275;
Andrew Scott
1Austin Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fred Saad
2Division of Urology, Centre hospitalier de l’Université de Montréal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Juneau
3Université de Montréal, Montreal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Brown
4Centre for Cancer Biology SA Pathology and University of South Australia, Adelaide SA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Kirkwood
5Royal Adelaide Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Nottage
5Royal Adelaide Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Rhoden
6Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Kazakin
7Fusion Pharmaceuticals Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joanne Schindler
6Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Baca
8CDE Dosimetry
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Sparks
9CDE Dosimetry Services, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James OLeary
6Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Burak
6Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Article Information

vol. 63 no. supplement 2 2275

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online August 8, 2022.

Copyright & Usage 
© 2022

Author Information

  1. Andrew Scott1,
  2. Fred Saad2,
  3. Daniel Juneau3,
  4. Michael Brown4,
  5. Ian Kirkwood5,
  6. Michelle Nottage5,
  7. John Rhoden6,
  8. Julia Kazakin7,
  9. Joanne Schindler6,
  10. Nicholas Baca8,
  11. Richard Sparks9,
  12. James OLeary6 and
  13. Eric Burak6
  1. 1Austin Hospital
  2. 2Division of Urology, Centre hospitalier de l’Université de Montréal
  3. 3Université de Montréal, Montreal, QC, Canada
  4. 4Centre for Cancer Biology SA Pathology and University of South Australia, Adelaide SA
  5. 5Royal Adelaide Hospital
  6. 6Fusion Pharmaceuticals
  7. 7Fusion Pharmaceuticals Inc.
  8. 8CDE Dosimetry
  9. 9CDE Dosimetry Services, Inc

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: August 2022 to April 2025

AbstractFullPdf
Aug 20222900
Sep 2022900
Oct 20221300
Nov 2022900
Dec 20222200
Jan 20231400
Feb 20232500
Mar 20231700
Apr 2023700
May 20232400
Jun 20231800
Jul 2023800
Aug 20231200
Sep 20231000
Oct 20232700
Nov 20232200
Dec 20232500
Jan 20243100
Feb 20242800
Mar 20242500
Apr 20242900
May 20242400
Jun 20242100
Jul 20245700
Aug 20245400
Sep 20242800
Oct 20244900
Nov 20242100
Dec 20243000
Jan 20251200
Feb 20251600
Mar 20251600
Apr 20253300
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue supplement 2
August 1, 2022
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of Pre-Administration of Anti-IGF-1R Antibody FPI 1175 on the Dosimetry, Tumor Uptake, and Pharmacokinetics of the IGF-1R Targeted Theranostic Imaging Agent [111In] FPI 1547 in Patients with Solid Tumors
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Impact of Pre-Administration of Anti-IGF-1R Antibody FPI 1175 on the Dosimetry, Tumor Uptake, and Pharmacokinetics of the IGF-1R Targeted Theranostic Imaging Agent [111In] FPI 1547 in Patients with Solid Tumors
Andrew Scott, Fred Saad, Daniel Juneau, Michael Brown, Ian Kirkwood, Michelle Nottage, John Rhoden, Julia Kazakin, Joanne Schindler, Nicholas Baca, Richard Sparks, James OLeary, Eric Burak
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 2275;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Impact of Pre-Administration of Anti-IGF-1R Antibody FPI 1175 on the Dosimetry, Tumor Uptake, and Pharmacokinetics of the IGF-1R Targeted Theranostic Imaging Agent [111In] FPI 1547 in Patients with Solid Tumors
Andrew Scott, Fred Saad, Daniel Juneau, Michael Brown, Ian Kirkwood, Michelle Nottage, John Rhoden, Julia Kazakin, Joanne Schindler, Nicholas Baca, Richard Sparks, James OLeary, Eric Burak
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 2275;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Multiparametric molecular profiling of lesion heterogeneity and response to therapy in patients with aggressive multiple myeloma with combined 18F-FDG-PET/CT and 68Ga-Pentixafor-PET/MR
  • Total-body dynamic PET/CT imaging of 11C-Methionine in multiple myeloma
  • Head-to-head comparison of biodistribution and tumor uptake of [68Ga]FAPI versus [18F]FDG-PET/CT in bladder cancer: a pilot study
Show more Early Phase (Phase 0 or I) human studies

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire